NASDAQ$MLTX
MoonLake Immunotherapeutics · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
MLTX Q3 2024 — $350.0M revenue, 0.56 EPS
Results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results for the entire fiscal year or any other period. MoonLake Immunotherapeutics reported Q3 2024 results. Diluted EPS came in at $0.56. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $350.0M.
- Diluted EPS: $0.56.
- Operating income: $43.1M.
Headline financials
Revenue & EPS history
MoonLake · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q3 2024
+0.3%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+7.7%
Avg return
30 days after
41%
7 / 17 earnings
Positive
+23.1%
Q2 2022
Best reaction
-10.4%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.2% | -2.9% | -4.8% | |
| Q3 2025 | -2.8% | +11.0% | +40.7% | |
| Q1 2025 | +4.7% | -2.2% | +14.8% | |
| Q4 2024 | -4.5% | -2.5% | -2.1% | |
| Q3 2024 | +0.6% | +0.8% | +5.5% | |
| Q1 2024 | -4.2% | -8.1% | -4.7% | |
| Q4 2023 | -10.4% | -15.3% | -11.6% | |
| Q3 2023 | +7.1% | +16.6% | +57.3% | |
| Q2 2023 | +3.5% | +3.8% | -5.7% | |
| Q1 2023 | +0.2% | +5.5% | +9.6% | |
| Q4 2022 | -4.9% | -9.2% | -5.6% | |
| Q3 2022 | -0.1% | -5.4% | +4.0% | |
| Q2 2022 | +23.1% | +45.8% | +33.0% | |
| Q1 2022 | -6.1% | +4.3% | +2.6% | |
| Q2 2021 | -0.1% | +0.0% | -0.1% | |
| Q4 2021 | -0.1% | +0.0% | -0.1% | |
| Q3 2021 | -1.3% | -1.3% | -1.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro